N6-Adenosine Methylation (mA) RNA Modification: an Emerging Role in Cardiovascular Diseases.

N6-methyladenosine (mA) is the most abundant and prevalent epigenetic modification of mRNA in mammals. This dynamic modification is regulated by mA methyltransferases and demethylases, which control the fate of target mRNAs through influencing splicing, translation and decay. Recent studies suggest that mA modification plays an important role in the progress of cardiac remodeling and cardiomyocyte contractile function. However, the exact roles of mA in cardiovascular diseases (CVDs) have not been fully explained. In this review, we summarize the current roles of the mA methylation in the progress of CVDs, such as cardiac remodeling, heart failure, atherosclerosis (AS), and congenital heart disease. Furthermore, we seek to explore the potential risk mechanisms of mA in CVDs, including obesity, inflammation, adipogenesis, insulin resistance (IR), hypertension, and type 2 diabetes mellitus (T2DM), which may provide novel therapeutic targets for the treatment of CVDs.